2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MNK
  5. MNK2 Isoform

MNK2

 

MNK2 Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-100022
    Tomivosertib
    		Inhibitor 99.92%
    Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance.
  • HY-112424
    Tinodasertib
    		Inhibitor 99.69%
    Tinodasertib (ETC-206) is a selective MNK1 and MNK2 inhibitor with IC50s of 64 nM and 86 nM, respectively.
  • HY-112113
    SLV-2436
    		Inhibitor 98.53%
    SLV-2436 is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50s of 10.8 ?nM and 5.4 nM, respectively.
  • HY-146805
    EB1
    		Inhibitor 99.91%
    EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation.
  • HY-124638
    MNK inhibitor 9
    		Inhibitor 99.38%
    MNK inhibitor 9 is a potent and selective inhibitor of MNK1/2 with IC50 values of 0.003 µM and 0.003 µM for MNK1 and MNK2 respectively. MNK inhibitor 9 has good cell permeability. MNK inhibitor 9 can be used in tumor related research.
  • HY-W846144
    ETP-45835
    		Inhibitor
    ETP-45835 is slective and potent MNK inhibitor with IC50s of 575 nM and 646 nM for MNK1 and MNK2, respectively. ETP-45835 shows little activity against 24 other kinases. ETP-45835 inhibits eIF4E Ser209 phosphorylation in cells, and has anticancer effects.
  • HY-171146
    HSN748
    		Inhibitor
    HSN748 is a Ponatinib (HY-12047) analogue and a multikinase inhibitor. HSN748 has inhibitory activity on FLT3, ABL1, RET, PDGFRα/β, MNK1, MNK2 and other kinases. HSN748 can inhibit the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines and can be used in the study of leukemia.
  • HY-156511
    ETC-168
    		Inhibitor
    ETC-168 is a selective and oral active MNK inhibitor with the IC50 values of 23 and 43 nM against MNK1 and MNK2, respectively. ETC-168 shows antiproliferative efficacy in vivo and in vitro.
  • HY-146735
    MNK1/2-IN-6
    		Inhibitor
    MNK1/2-IN-6 is a potent and selective MNK1/2 inhibitor with IC50s of 2.3 nM and 3.4 nM for MNK1 and MNK2, respectively. MNK1/2-IN-6 induces apoptosis in a concentration-dependent manner.
  • HY-115906
    K783-0308
    		Inhibitor
    K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC50 values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC50=10.5 µM) and MV-4-11 (IC50=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase.
  • HY-158438
    MNK1/2-IN-8
    		Inhibitor
    MNK1/2-IN-8 (compound 15b) is a MNK1/2 inhibitor with the IC50 values of 0.8 and 1.5 nM against Mnk1 and Mnk2. MNK1/2-IN-8 shows anti-proliferative activity and induces cell cycle arrest.
  • HY-163479
    MNK1/2-IN-7
    		Inhibitor
    MNK1/2-IN-7 (compound 20j) is an orally available inhibitor of MNK1/2 with anticancer activity and hERG safety. MNK1/2-IN-7 also inhibits the phosphorylation of eIF4E, inhibiting the MNK/eIF4E signaling pathway and cancer cell proliferation. MNK1/2-IN-7 is synergistic with Ibrutinib (HY-109970).